^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SL-172154

    i
    Other names: SL-172154, SIRPα-Fc-CD40L, SL172154, SL 172154
    Associations

    News

    Trials
    Company:
    Shattuck
    Drug class:
    CD47 inhibitor, CD40 agonist
    Related drugs:
    Associations

    News

    Trials
    15d
    SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
    P1, N=106, Terminated, Shattuck Labs, Inc. | Completed --> Terminated; Development discontinued
    Trial termination
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • SL-172154
    1year
    SL03-OHD-105: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (clinicaltrials.gov)
    P1, N=86, Completed, Shattuck Labs, Inc. | Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Feb 2025 | Trial primary completion date: Nov 2024 --> Feb 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
    1year
    SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML (clinicaltrials.gov)
    P1, N=106, Completed, Shattuck Labs, Inc. | Active, not recruiting --> Completed | N=160 --> 106 | Trial completion date: Nov 2024 --> Feb 2025 | Trial primary completion date: Nov 2024 --> Feb 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • SL-172154
    1year
    First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. (PubMed, J Immunother Cancer)
    SL-172154 was tolerable as monotherapy and induced, dose-dependent, and cyclical immune cell activation, increases in multiple serum cytokines, and trafficking of CD40-positive B cells and monocytes following each infusion. The safety, PK, and PD activity support 3.0 mg/kg as a safe and pharmacologically active dose.
    P1 data • Journal
    |
    CD8 (cluster of differentiation 8) • CD40 (CD40 Molecule) • CD40LG (CD40 ligand) • SIRPA (Signal Regulatory Protein Alpha)
    |
    SL-172154
    over1year
    SL03-OHD-105: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (clinicaltrials.gov)
    P1, N=86, Active, not recruiting, Shattuck Labs, Inc. | Trial completion date: Apr 2025 --> Nov 2024
    Trial completion date
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
    over1year
    SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, Shattuck Labs, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Nov 2024 | Trial primary completion date: Apr 2025 --> Nov 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • SL-172154
    over1year
    SL03-OHD-105: Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers (clinicaltrials.gov)
    P1, N=86, Active, not recruiting, Shattuck Labs, Inc. | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial primary completion date
    |
    FOLR1 ( Folate receptor alpha )
    |
    pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
    almost2years
    Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers (clinicaltrials.gov)
    P1, N=86, Active, not recruiting, Shattuck Labs, Inc. | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    FOLR1 ( Folate receptor alpha )
    |
    pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
    2years
    03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
    P1, N=160, Recruiting, Shattuck Labs, Inc. | N=107 --> 160 | Trial completion date: Oct 2024 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Apr 2025
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • SL-172154
    over2years
    03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
    P1, N=107, Recruiting, Shattuck Labs, Inc.
    Trial completion date • Trial primary completion date • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • SL-172154
    over2years
    Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers (clinicaltrials.gov)
    P1, N=102, Enrolling by invitation, Shattuck Labs, Inc. | Recruiting --> Enrolling by invitation | Phase classification: P1b --> P1
    Enrollment status • Phase classification
    |
    FOLR1 ( Folate receptor alpha )
    |
    pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
    over2years
    Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
    P1, N=107, Recruiting, Shattuck Labs, Inc. | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • SL-172154